Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-17
- Development stage
- Preclinical
- Lead developer
- CKD Bio
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
CKDB-17 is an investigational active pharmaceutical ingredient (API) being developed by CKD Bio, a subsidiary of Chong Kun Dang, for the treatment of dry eye disease. CKD Bio specializes in the production of complex molecules through fermentation technology, and CKDB-17 is part of their specialized API pipeline targeting ophthalmic conditions. While specific mechanistic details and the exact molecular target have not been publicly disclosed, the candidate is positioned within the company's research and development sector as a potential therapeutic for managing the symptoms and underlying causes of dry eye disease.
Beyond the preview
Go deeper on CKDB-17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKDB-17.